Cystic Fibrosis Devices Global Strategic Business Report 2024: Market to Reach $1.6 Billion by 2030 AbbVie, Allergan Plc, AstraZeneca at the Forefront
June 13, 2024 05:57 ET
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Devices - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cystic...
Novotech Publishes Analyst Report on Cystic Fibrosis Clinical Trial Landscape to Inform Biotech Research Planning
April 10, 2024 22:33 ET
|
Novotech
The report presents a data-backed review of the Cystic Fibrosis (CF) funding landscape, trial density, and patient recruitment data.
Global Cystic Fibrosis Market Analysis & 10 Year Forecast 2024-2034: By Drug Class, CFTR Modulators was the Highest Revenue-Grossing Segment in the Global Cystic Fibrosis Market in 2023
April 09, 2024 04:13 ET
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global cystic...
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
March 05, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Soft Mist Inhalers Market Size Projected to Grow at a 6.8% CAGR, Globally, by 2031 - Exclusive Report by Transparency Market Research, Inc.
February 29, 2024 01:45 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global soft mist inhalers market is projected to grow at a CAGR of 6.8% from 2022 to...
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
February 13, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Respiratory Devices Market Size to be Worth USD 37.7 billion by 2031, with Notable CAGR of 6.1%| Transparency Market Research, Inc.
January 08, 2024 08:44 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global respiratory devices market is estimated to flourish at a CAGR of 6.1% from 2023...
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
November 13, 2023 02:00 ET
|
ViaNautis Bio
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver...